Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
91 hedge funds and large institutions have $149M invested in Melinta Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 10 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
5% more funds holding
Funds holding: 87 → 91 (+4)
22% less call options, than puts
Call options by funds: $371K | Put options by funds: $476K
39% less capital invested
Capital invested by funds: $246M → $149M (-$97M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$9.64M |
| 2 |
BlackRock
New York
|
+$3.88M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.2M |
| 4 |
JP Morgan Chase
New York
|
+$2.09M |
| 5 |
First Manhattan
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14M |
| 2 |
DM
Deerfield Management
New York
|
-$8.51M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.42M |
| 4 |
Millennium Management
New York
|
-$2.06M |
| 5 |
Renaissance Technologies
New York
|
-$692K |
MLNT Hedge Fund Activity: Q3 2018 in Review
91 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q3 2018, worth a combined $149M — down 39% from $246M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MLNT positions and 10 closed out — a net gain of 4 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $9.64M. The largest seller was Fidelity Investments, cutting an estimated $14M.
- 91 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q3 2018, up from 87 in Q2 2018.
- Funds reported $149M of Melinta Therapeutics, Inc. Common Stock stock for Q3 2018, down 39% quarter-over-quarter.
- 14 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q3 2018 and 10 closed out, a net change of +4 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q3 2018 was Stonepine Capital Management, an estimated $9.64M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $14M sold.
Based on aggregated 13F filings for Q3 2018.